| 查看: 780 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
0860004 求调剂 309分
已经有4人回复
-
材料类284调剂
已经有25人回复
-
一志愿211 0703化学 346分求调剂
已经有5人回复
-
考研调剂-材料类-284
已经有17人回复
-
280求调剂
已经有3人回复
-
0703化学求调剂
已经有18人回复
-
调剂
已经有15人回复
-
复试调剂，一志愿郑州大学材料与化工289分
已经有16人回复
-
349学科化学045106求调剂，化学类都可以
已经有7人回复
-
086003调剂求助
已经有6人回复
» 抢金币啦！回帖就可以得到:
-
沈阳化工大学环境学院生物与医药、药学、化学、安全工程、环境工程等可调剂，名额充裕
+1/482
-
专硕（资源与环境、土木水利），接收跨专业，工学、理学都行！
+1/90
-
江西科技师范大学 材料与能源招收调剂研究生
+1/85
-
广东石油化工学院，材料与化工、能源动力专硕，招收调剂生，线上面试
+2/56
-
湖北汽车工业学院汽车材料学院2026年接收调剂研究生（新能源电池方向）
+2/50
-
招收2026级公共卫生与预防医学专业（学硕）调剂生1名
+1/43
-
延安大学国家级高层次人才团队招收材料、化学、化工相关领域调剂研究生数名
+1/41
-
0860接收报考07，08，09，10的部分专业可调！
+1/40
-
江西科技师范大学分析化学专业段学民教授课题组招聘调剂学生
+1/39
-
西安-纺织科学与工程（纺织化学与染整）、材料与化工
+1/22
-
南华大学招收调剂生，[085700]资源与环境—环境工程方向
+1/12
-
齐齐哈尔大学李莉课题组诚招2026级考研调剂生（学硕和专硕）
+1/8
-
招调剂_北京农学院_植物保护系_昆虫方向_专硕_学硕各1名
+1/6
-
齐齐哈尔大学李莉课题组诚招2026级考研调剂生（学硕和专硕）
+1/6
-
找好工作来我这-广东唯一石化院校——资源与环境专硕招生
+1/5
-
国家大人才课题组招收化学、材料化工类2026年调剂生
+1/5
-
合工大具身智能柔性机器人方向招博士
+1/3
-
河南城建学院招收土木与水利、资源与环境调剂生
+1/3
-
渤海大学材料与化工专硕调剂
+1/2
-
【#上海调剂急录#】能接受985联合培养的速来！带你发一区文章！
+1/2
10楼2011-01-12 10:59:22
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
